Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.

Although response rates to ICIs for BM are poor, patients treated with ICI plus denosumab for bone metastases with impending fractures from NSCLC and melanoma are likely to avoid surgery to prevent fractures.